What does PHARMGETH do?

PHARMGETH is a property company in Mesen. Public Limited, started on 28 March 2000, 1 establishment.

What is the address of PHARMGETH?

The registered office of PHARMGETH is located at Ketelstraat 11, 8957 Mesen.

Is PHARMGETH still active?

Yes. According to the CBE (30 October 2026) PHARMGETH is active, legal situation “Normale toestand”, started on 28 March 2000.

Is PHARMGETH registered on Peppol?

Yes, PHARMGETH is registered on the Peppol network with ID 0208:0471524819.

What is the enterprise number of PHARMGETH?

The enterprise number of PHARMGETH is BE0471524819.

When was PHARMGETH founded?

PHARMGETH was founded on 28 March 2000.

Who are the directors of PHARMGETH?

According to the 2025 annual accounts, the directors of PHARMGETH are: Filip Vansteelant, Jocelyne Leterme.

Is PHARMGETH a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 March 2000; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMGETH make in 2025?

PHARMGETH recorded a loss after taxes of € 5,383 in financial year 2025.

What is the revenue of PHARMGETH?

As a small company, PHARMGETH is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 98,592.

How much does an employee at PHARMGETH earn?

The average wage cost per full-time employee at PHARMGETH was € 60,100 in 2025: staff costs of € 60,084 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMGETH have?

According to the 2025 annual accounts, PHARMGETH has 1 full-time equivalents (FTE).

PHARMGETH (Public Limited) - Mesen - BE0471524819

Dossier PHARMGETH, printed on 30 October 2026 from databakkes.be/en/0471524819/pharmgeth. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 18 % of short-term debt in 2025; threshold 65 %.
Late annual account NBB

Fiscal year 2025 was filed 228 days after the legal deadline.

Financials

Financial year 2025

PHARMGETH from Mesen, company number BE0471524819, closed financial year 2025 with a result of € -5,383 after tax. For that financial year PHARMGETH recorded a gross margin of € 98,592 and equity of € 668,073. Compared with financial year 2024, the result moved from € 9,701 to € -5,383. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 15, 2026.

What it is worth Healthy

€ 668,073

▼ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -5,383

▼ still € 9,701 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 5,299

▲ € 4,895 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 286,073.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 60,084

▲ 2% vs 2024

€ 60,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 589

▼ 87% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 30,959

▼ 36% vs 2024

€ 14,286 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 9,224

▲ 72% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 33,704

▼ 28% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 153,193 Gross margin 2022: € 153,193 First fiscal year in the series	€ 146,640 Gross margin 2023: € 146,640 ▼ 4% vs 2022 (€ 153,193) Unfavourable step	€ 119,673 Gross margin 2024: € 119,673 ▼ 18% vs 2023 (€ 146,640) Unfavourable step	€ 98,592 Gross margin 2025: € 98,592 ▼ 18% vs 2024 (€ 119,673) Unfavourable step	▼ 18%
Profit after taxes	€ 47,386 Profit after taxes 2022: € 47,386 First fiscal year in the series	€ 27,521 Profit after taxes 2023: € 27,521 ▼ 42% vs 2022 (€ 47,386) Unfavourable step	€ 9,701 Profit after taxes 2024: € 9,701 ▼ 65% vs 2023 (€ 27,521) Unfavourable step	€ -5,383 Profit after taxes 2025: € -5,383 ▼ € 15,085 vs 2024 (€ 9,701) Unfavourable step	▼ € 15,085
Equity	€ 641,686 Equity 2022: € 641,686 First fiscal year in the series	€ 677,492 Equity 2023: € 677,492 ▲ 6% vs 2022 (€ 641,686) Favourable step	€ 687,193 Equity 2024: € 687,193 ▲ 1% vs 2023 (€ 677,492) Favourable step	€ 668,073 Equity 2025: € 668,073 ▼ 3% vs 2024 (€ 687,193) Unfavourable step	▼ 3%
Total debts	€ 633,919 Total debts 2022: € 633,919 First fiscal year in the series	€ 619,213 Total debts 2023: € 619,213 ▼ 2% vs 2022 (€ 633,919) Favourable step	€ 480,658 Total debts 2024: € 480,658 ▼ 22% vs 2023 (€ 619,213) Favourable step	€ 461,192 Total debts 2025: € 461,192 ▼ 4% vs 2024 (€ 480,658) Favourable step	▼ 4%
Cash	€ 37,244 Cash 2022: € 37,244 First fiscal year in the series	€ 43,580 Cash 2023: € 43,580 ▲ 17% vs 2022 (€ 37,244) Favourable step	€ 404 Cash 2024: € 404 ▼ 99% vs 2023 (€ 43,580) Unfavourable step	€ 5,299 Cash 2025: € 5,299 ▲ € 4,895 vs 2024 (€ 404) Favourable step	▲ € 4,895
Land & buildings	€ 268,178 Land & buildings 2022: € 268,178 First fiscal year in the series	€ 243,124 Land & buildings 2023: € 243,124 ▼ 9% vs 2022 (€ 268,178) Unchanged	€ 218,316 Land & buildings 2024: € 218,316 ▼ 10% vs 2023 (€ 243,124) Unchanged	€ 193,507 Land & buildings 2025: € 193,507 ▼ 11% vs 2024 (€ 218,316) Unchanged	▼ 11%
Retained profit	€ 259,686 Retained profit 2022: € 259,686 First fiscal year in the series	€ 295,492 Retained profit 2023: € 295,492 ▲ 14% vs 2022 (€ 259,686) Favourable step	€ 305,193 Retained profit 2024: € 305,193 ▲ 3% vs 2023 (€ 295,492) Favourable step	€ 286,073 Retained profit 2025: € 286,073 ▼ 6% vs 2024 (€ 305,193) Unfavourable step	▼ 6%
Dividend	€ 26,314 Dividend 2022: € 26,314 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 26,314) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 13,736 Dividend 2025: € 13,736 Unchanged (€ 0) Unchanged
Bank debt	€ 106,785 Bank debt 2022: € 106,785 First fiscal year in the series	€ 77,004 Bank debt 2023: € 77,004 ▼ 28% vs 2022 (€ 106,785) Favourable step	€ 48,000 Bank debt 2024: € 48,000 ▼ 38% vs 2023 (€ 77,004) Favourable step	€ 30,959 Bank debt 2025: € 30,959 ▼ 36% vs 2024 (€ 48,000) Favourable step	▼ 36%
Balance sheet total	€ 1,380,790 Balance sheet total 2022: € 1,380,790 First fiscal year in the series	€ 1,392,382 Balance sheet total 2023: € 1,392,382 ▲ 1% vs 2022 (€ 1,380,790) Unchanged	€ 1,262,306 Balance sheet total 2024: € 1,262,306 ▼ 9% vs 2023 (€ 1,392,382) Unchanged	€ 1,222,496 Balance sheet total 2025: € 1,222,496 ▼ 3% vs 2024 (€ 1,262,306) Unchanged	▼ 3%
Employees (FTE)	0.4 Employees (FTE) 2022: 0.4 First fiscal year in the series	1 Employees (FTE) 2023: 1 ▲ 0.6 vs 2022 (0.4) Unchanged	1 Employees (FTE) 2024: 1 Unchanged (1) Unchanged	1 Employees (FTE) 2025: 1 Unchanged (1) Unchanged

Key figures of PHARMGETH, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to PHARMGETH?

What happened at PHARMGETH in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Filip Vansteelant stepped down as director. NBB
2029 Jocelyne Leterme stepped down as director. NBB
Sep 15, 2026 New annual accounts for financial year 2025: loss of € 5,383 (▼ € 15,085 vs 2024). filed late Source: NBB ↗
2023 Filip Vansteelant became a director. NBB
2023 Jocelyne Leterme became a director. NBB
May 17, 2000 New establishment in Comines-Warneton. KBO
Mar 28, 2000 Start of the company according to the CBE. KBO

In short

From € 47,386 profit in 2022 to € 5,383 loss in 2025.

Paid € 75,860 in corporate taxes since 2022.

Best year ever: 2022, with € 47,386 profit.

On average € 98,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

PHARMGETH

Pharmacie Castrique 98.4%

It owns 98.4% of Pharmacie Castrique itself.

Directors

According to the 2025 annual accounts

Filip Vansteelant

Director

Also active at: PENTA APOTHEEK

since 2023 · until 2029

Jocelyne Leterme

Director

Also active at: PHARMACIE CASTRIQUE, PENTA APOTHEEK

since 2023 · until 2029

Establishments

Establishment units

Physical locations of this company

Registered office

Ketelstraat 11

8957 Mesen

2.100.773.639

Stationstraat(KOM) 51

7780 Comines-Warneton

Active since 17 May 2000

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0471.524.819

VAT number

BE 0471.524.819

Registered office

Ketelstraat 11, 8957 Mesen

Names & denominations

PHARMGETH

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

28 March 2000

Peppol

Active · Active since 25 Nov 2025

Activities · NACE

Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMGETH

Warning lights

Financials

What happened to PHARMGETH?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions